
    
      This Phase I study will consist of a dose escalation portion which includes a dose escalation
      phase of 10 dose levels: (1a) docetaxel 60 mg/m2, pazopanib 400 mg daily, prednisone 5 mg
      BID; (2a) docetaxel 75 mg/m2, pazopanib 400 mg daily, prednisone 5 mg BID; and (3a) docetaxel
      75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID; (4a) docetaxel 75mg/m2, pazopanib 800
      mg daily, (5a) docetaxel 75mg/m2, pazopanib 1000mg daily, prednisone 5 mg; (1b) docetaxel 60
      mg/m2, pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; (2b) docetaxel 75 mg/m2,
      pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; and (3b) docetaxel 75 mg/m2, pazopanib
      600 mg daily x 17 days, prednisone 5 mg BID; (4b) docetaxel 75mg/m2, pazopanib 800 mg daily x
      17 days, (5b) docetaxel 75mg/m2, pazopanib 1000mg daily x 17 days, prednisone 5 mg. If the
      investigators see > 1 dose limiting toxicity (DLT) at Dose level 3 then the investigators
      would investigate docetaxel 75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID (Dose level
      3a). If < 1 DLT are seen at Dose level 3 and Pharmacokinetic (PK) analysis is complete and
      acceptable, then the investigators will proceed to dose level 4) docetaxel 75 mg/m2,
      pazopanib 1000 mg daily, prednisone 5 mg BID.

      The investigators will dose escalate in a classic 3+3 design. The maximum tolerated dose
      (MTD) will be defined as the highest dose level that does not result in 2 or more dose
      limiting toxicities (DLTs). A dose expansion at the MTD of 10-15 patients (up to a total of
      36 patients) will be accrued in order to further describe the safety profile.
    
  